Abstract:Background Doxorubicin is one of the most effective chemotherapeutic drugs for breast cancer while its common drug resistance leads to poor patient prognosis and survival. Growing evidence indicate dynamically reorganized chromatin allows rapid access of the gene regulatory machinery to open genomic regions facilitating subsequent gene expression through direct transcription factor (TF) activation and regulatory element binding. Methods To better understand the regulatory network underlying doxorubicin resistance in breast cancer cells, we explored the systematic alterations of chromatin accessibility and gene expression by the assay for transposase-accessible chromatin using sequencing (ATAC-seq) in combination with RNA sequencing, followed by integrative analysis to identify potential regulators and their targets associated with differentially accessible regions (DARs) in doxorubicin-resistant MCF7 (MCF7-DR) cells. Results A total of 3,963 differentially expressed genes (DEGs) related to doxorubicin resistance were identified, including dramatically up-regulated MT1E , GSTP1 , LDHB , significantly down-regulated TFF1 , UBB , DSCAM-AS1 , and histone-modifying enzyme coding genes HDAC2 , EZH2 , PRMT5 , etc. By integrating with transcriptomic datasets, we identified 18,228 DARs in MCF7-DR cells compared to control, which were positively correlated with their nearest DEGs ( r = 0.6). There were 11,686 increased chromatin-accessible regions, which were enriched in up-regulated genes related to diverse KEGG pathways, such as the cell cycle, regulation of actin cytoskeleton, signaling pathways of MAPK, PI3K/Akt and Hippo, which play essential roles in regulating cell apoptosis, proliferation, metabolism, and inflammatory responses. The 6,542 decreased chromatin-accessible regions were identified for the declined doxorubicin-associated biological processes, for instance, endocrine and insulin resistance, central carbon metabolism, signaling pathways of TGF-beta and P53. Combining data from TCGA, analyses of the DAR sequences associated with the DNA-binding motifs of significantly enriched TF families including AP-1, TEAD and FOX, indicated that the loss-function of FOXA1 might play a critical role in doxorubicin-resistant breast cancer cells (DOX-R BCCs). Conclusion These data exhibit the non-genetic landscape of chromatin accessibility and transcript levels in the DOX-R BCCs, and provide clear insights and resources for the detection of critical TFs and potential cis -regulatory elements-based putative therapeutic targets.

Histone Deacetylase 2 Regulates the Doxorubicin (dox) Resistance of Hepatocarcinoma Cells and Transcription of ABCB1

Histone Deacetylase 2 Regulates Doxorubicin (dox) Sensitivity of Colorectal Cancer Cells by Targeting Abcb1 Transcription

Knockdown of Eukaryotic Translation Initiation Factor 5A2 Enhances the Therapeutic Efficiency of Doxorubicin in Hepatocellular Carcinoma Cells by Triggering Lethal Autophagy

Chemoresistance is Associated with Overexpression of HAX-1, Inhibition of Which Resensitizes Drug-Resistant Breast Cancer Cells to Chemotherapy.

Analysis of ABCG2 Expression and Side Population Identifies Intrinsic Drug Efflux in the HCC Cell Line MHCC-97L and Its Modulation by Akt Signaling.

Pharmacological or Transcriptional Inhibition of Both HDAC1 and 2 Leads to Cell Cycle Blockage and Apoptosis Via P21waf1/cip1 and P19ink4d Upregulation in Hepatocellular Carcinoma.

Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma.

CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma.

HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness

Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells

Identification of Histone Deacetylase 3 As a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-associated Hepatocellular Carcinoma.

Sensitization to Oxidative Stress and G2/M Cell Cycle Arrest by Histone Deacetylase Inhibition in Hepatocellular Carcinoma Cells.

Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization

TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.

HDAC2 Regulates Cell Proliferation, Cell Cycle Progression and Cell Apoptosis in Esophageal Squamous Cell Carcinoma EC9706 Cells

FOXA2 Inhibits Doxorubicin-Induced Apoptosis Via Transcriptionally Activating HBP Rate-Limiting Enzyme GFPT1 in HCC Cells

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer

The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells

Genetic Alterations In Doxorubicin-Resistant Hepatocellular Carcinoma Cells: A Combined Study Of Spectral Karyotyping, Positional Expression Profiling And Candidate Genes

HDAC8-dependent Deacetylation of PKM2 Directs Nuclear Localization and Glycolysis to Promote Proliferation in Hepatocellular Carcinoma.

Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells